Hypertension
Conditions
Keywords
Hypertension, benazepril, hydrochlorothiazide, fixed combination
Brief summary
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.
Interventions
DRUGBenazepril plus hydrochlorothiazide
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients, age 18 or older * Given informed consent * Diagnosed as having mild to moderate essential hypertension
Exclusion criteria
* Severe hypertension * Significant preexisting cardiovascular and cerebrovascular disease * Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II * Advanced renal impairment Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in diastolic blood pressure from baseline to week 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in systolic blood pressure from baseline to week 8 | — |
| Proportion of patients with blood pressure less than 140/90 mmHg at week 8 | — |
| Ambulant blood pressure monitoring profiles at baseline and week 8 | — |
Countries
China
Outcome results
None listed